
Research and development of gene therapy medicines for the treatment of rare diseases.
C
CSR Analysis score
The organization is among the 50% most committed organizations, excluding the top 20%, among comparable organizations.
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: August 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Ipsen
B
Research, innovation, and development of transformative medicines in oncology, rare diseases, and neuroscience.
Orphan Europe
B
Development and provision of medicines for rare diseases in endocrinology, oncology-hematology, and metabolic therapy areas.
GenSight Biologics
B
Development of gene therapies for the treatment of blindness, focusing on mitochondrial targeting and optogenetics.
Initiatives identified among leaders
Rémunération variable liée à performance financière et RSE
“La politique de rémunération des mandataires socia...” - IpsenDéveloppement des talents et renforcement de la diversité en entreprise
“Le groupe Recordati met en œuvre des actions pour ...” - Orphan EuropeReconnaissance climatique via CDP A-List et validation SBTi
“Ipsen a renforcé son engagement climatique en obte...” - Ipsen48% of similar organizations communicate on CSR issues
+335 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports